Australia's most trusted
source of pharma news
Posted 22 September 2021 PM
Another round of analysis of mRNA Covid jabs has found that when it comes to initial effectiveness Pfizer and Moderna vaccines are just about neck-and-neck but when measuring effectiveness over time, the gap widens with Moderna's Spikevax offering better results ahead of Pfizer's Comirnaty.
The new study published in the Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report found from March to August 2021, the vaccine effectiveness against hospitalisation was 93 per cent for two doses of Moderna's vaccine and 88 per cent for two doses of Pfizer's jab.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.